VR Logo

Immunome Inc. (IMNM) download report


Healthcare | Biotechnology & Pharma Research

Immunome Inc. (IMNM) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.

IPO Date: 02-Oct-2020

Pres, CEO & Director: Dr. Purnanand Duddu Sarma Ph.D.

Chief Financial Officer: Ms. Corleen M. Roche

Listing: NASDAQ: IMNM

Country: United States

Headquarters: Exton, PA

Website: https://immunome.com

Key Facts

Market cap: $35.78 Mln

Revenue (TTM): $0.51 Mln

Earnings (TTM): $-32.47 Mln

Cash: $42.88 Mln

Total Debt: $0.21 Mln

Insider's Holding: 20.00%

Liquidity: Low

52 Week range: $2.09 - 27.80

Shares outstanding: 12,127,400

Stock Performance

Time Period Immunome (IMNM) S&P BSE Sensex* S&P Small-Cap 600*
YTD-78.09-8.71-17.14
1 month-12.62-3.11-4.85
3 months-41.08-7.29-12.74
1 Year-84.050.48-16.37
3 Years--10.347.97
5 Years--11.436.33
10 Years--12.1010.54
As on 27-Jun-2022 *As on 28-Jun-2022
Year Immunome (IMNM) S&P Small-Cap 600 S&P BSE Sensex
202133.8825.2721.99